172@29@17@102!~!172@29@0@53!~!|news|ipcalabs|results-IL-3months-2.html!~!news|moneycontrol|com!~!|controller|tag.php!~!is_mobile=false
Moneycontrol
you are here: HomeNewsIpcalabs
results
Jump to
26 Results Found
  • Ipca Labs Q2 PAT seen up 34% YoY to Rs. 160.2 cr: Emkay Oct 14, 2019 04:12 PM IST

    Ipca Labs Q2 PAT seen up 34% YoY to Rs. 160.2 cr: Emkay

    Net Sales are expected to increase by 12.8 percent Y-o-Y (up 11.3 percent Q-o-Q) to Rs. 1,125.4 crore, according to Emkay.

  • IPCA Laboratories Q1 PAT seen up 34.1% YoY to Rs. 87.9 cr: Prabhudas Lilladher Jul 12, 2019 05:08 PM IST

    IPCA Laboratories Q1 PAT seen up 34.1% YoY to Rs. 87.9 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 14 percent Y-o-Y (up 16.8 percent Q-o-Q) to Rs. 973.5 crore, according to Prabhudas Lilladher.

  • IPCA Laboratories Q4 PAT seen up 106.1% YoY to Rs. 105.8 cr: Prabhudas Lilladher Apr 12, 2019 01:13 PM IST

    IPCA Laboratories Q4 PAT seen up 106.1% YoY to Rs. 105.8 cr: Prabhudas Lilladher

    Net Sales are expected to increase by 24.2 percent Y-o-Y (up 2.5 percent Q-o-Q) to Rs. 970.8 crore, according to Prabhudas Lilladher.

  • IPCA Labs Q3 PAT seen up 1.5% YoY to Rs. 107.2 cr: ICICI Direct Jan 11, 2019 05:36 PM IST

    IPCA Labs Q3 PAT seen up 1.5% YoY to Rs. 107.2 cr: ICICI Direct

    Net Sales are expected to increase by 9.3 percent Y-o-Y (down 7.3 percent Q-o-Q) to Rs. 939.1 crore, according to ICICI Direct.

  • IPCA Labs Q2 PAT may dip 7.3% YoY to Rs. 89.4 cr: ICICI Direct Oct 12, 2018 05:02 PM IST

    IPCA Labs Q2 PAT may dip 7.3% YoY to Rs. 89.4 cr: ICICI Direct

    Net Sales are expected to increase by 10 percent Y-o-Y (up 11.3 percent Q-o-Q) to Rs. 950.5 crore, according to ICICI Direct.

  • IPCA Laboratories Q4 PAT seen up 209.3% YoY to Rs. 83.8 cr: Edelweiss Apr 16, 2018 06:13 PM IST

    IPCA Laboratories Q4 PAT seen up 209.3% YoY to Rs. 83.8 cr: Edelweiss

    Net Sales are expected to increase by 19.4 percent Y-o-Y (down 7.5 percent Q-o-Q) to Rs. 795.1 crore, according to Edelweiss.

  • IPCA Q1 PAT seen up 153% to Rs 95.4 cr: Edelweiss Jul 14, 2016 06:17 PM IST

    IPCA Q1 PAT seen up 153% to Rs 95.4 cr: Edelweiss

    Net Sales are expected to increase by 34.5 percent Q-o-Q (up 10.9 percent Y-o-Y) to Rs 840.4 crore, according to Edelweiss

  • Buy IPCA; it is well valued for long-term investors: Angel Nov 10, 2014 01:48 PM IST

    Buy IPCA; it is well valued for long-term investors: Angel

    Sarabjit Kaur Nangra of Angel Broking says the stock is very well valued at the current prices and adds that the company‘s cautiousness about maintaining its profitability is a positive.

  • Pharma companies revenues to rise 12% in Q3: Anand Rathi Jan 03, 2014 05:34 PM IST

    Pharma companies revenues to rise 12% in Q3: Anand Rathi

    Pharma companies are likely to post 12 percent Y-o-Y revenue growth. However, excluding Wockhardt (FDA issues) and Fortis Healthcare (divestments), revenue growth is expected to be 19 percent Y-o-Y.

  • See India biz grow 15%, exports to rise 25% in H2: Ipca Oct 25, 2013 11:56 AM IST

    See India biz grow 15%, exports to rise 25% in H2: Ipca

    Ipca Labs hopes to continue doing very well in H2FY14 especially in its India formulation business, says ED AK Jain. It is awating USFDA approvals for Indore SEZ which, the company feels will boost its business going forward.

  • May revise guidance upwards post Q2: Ipca Labs Jul 30, 2013 04:11 PM IST

    May revise guidance upwards post Q2: Ipca Labs

    AK Jain, ED, Ipca Labs told CNBC-TV18 that the start of the earnings for the company is very good and down the line maybe after Q2 it may revise the guidance.

  • Pharma cos likely to post 21% EBITDA growth in Q4: MOST Apr 16, 2013 01:30 PM IST

    Pharma cos likely to post 21% EBITDA growth in Q4: MOST

    Motilal Oswal has come with its March`13 quarterly earning estimates for healthcare sector. The research firm expects a top line growth of 17.4% YoY and EBITDA growth of 21.3% YoY for our pharma universe (excluding one-offs).

  • Improvement in gross margins likely to continue: Ipca Labs Feb 04, 2013 01:11 PM IST

    Improvement in gross margins likely to continue: Ipca Labs

    Last week, Ipca Laboratories reported net profit of Rs 87.89 crore for the quarter ending December 31, 2012 on the back of strong sales across domestic and international markets. AK Jain, ED, Ipca Laboratories told CNBC-TV18 that the margins are going to remain in the regions of around 32 percent plus.

  • Good performance likely from pharma in Q3: Nirmal Bang Jan 12, 2013 03:52 PM IST

    Good performance likely from pharma in Q3: Nirmal Bang

    Nirmal Bang has come out with its earnings estimates for pharmaceutical sector for the quarter ended December 2012. The research firm feels margins of pharma companies may witness YoY expansion owing to rupee depreciation (6 percent YoY).

  • See pharma sector's Q3 topline to grow 22%: Motilal Oswal Jan 12, 2013 11:54 AM IST

    See pharma sector's Q3 topline to grow 22%: Motilal Oswal

    Motilal Oswal has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects the topline to grow by 22 percent, EBITDA by 21 percent on the back of strong operational performance by Ranbaxy, Glenmark, Strides, Torrent and Divi's.

  • See pharma sector's Q3 adj PAT to grow 26% YoY: P Lilladher Jan 12, 2013 10:57 AM IST

    See pharma sector's Q3 adj PAT to grow 26% YoY: P Lilladher

    Prabhudas Lilladher has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects top-line growth of 24 percent YoY for its coverage universe (excluding one-offs), with EBITDA growth at a robust 24 percent YoY.

  • See pharma sector's margins to dip 314 bps in 3QFY13: Angel Jan 08, 2013 05:10 PM IST

    See pharma sector's margins to dip 314 bps in 3QFY13: Angel

    Angel Broking has come out with earning expectations for pharmaceutical sector for the October-December quarter of 2012. The research firm expects the Indian pharma sector to post lackluster numbers for 3QFY2013 on the sales front.

  • See strong performance by pharma in Mar quarter: KR Choksey Apr 05, 2012 02:45 PM IST

    See strong performance by pharma in Mar quarter: KR Choksey

    According to the report on earnings preview for the quarter ended March 2012, KR Choksey expects the pharma sector will show strong performance in the domestic pharmaceuticals market mainly due to recovery in Indian pharma market.

  • Pharma Q3: New launches, generic drug demand to aid growth Jan 14, 2012 01:37 PM IST

    Pharma Q3: New launches, generic drug demand to aid growth

    Pharmaceutical companies are expected to report healthy 15-25% year-on-year revenue growth in the third quarter, helped by new launches especially in the US and strong demand for generic drugs.

  • Pharmaceutical results preview for Q3FY12: Emkay Jan 10, 2012 06:34 PM IST

    Pharmaceutical results preview for Q3FY12: Emkay

    Emkay Global Financial Services has come with its December quarterly earning estimates for pharmaceutical sector. According to the research firm the sector is expected to report a growth of 18% YoY (5% QoQ) in revenues partly driven by Rupee depreciation which is likely to be 4-5% of the overall growth.

  • Ipca Labs eyes 20% export growth in second half of FY12 Nov 01, 2011 03:56 PM IST

    Ipca Labs eyes 20% export growth in second half of FY12

    Executive Director of Ipca Labs AK Jain tells CNBC-TV18 that they aim to grow exports by 20% in the second half of the current fiscal year.

  • IPCA Labs Sept qtr PAT seen up 20% at Rs 78.4 cr Oct 11, 2011 12:00 PM IST

    IPCA Labs Sept qtr PAT seen up 20% at Rs 78.4 cr

    Dolat Capital has come out with its earning estimates on Pharma sector for the quarter ended September 2011. According to the research firm, IPCA Labs September quarter net sales are expected to go up by 16.3% at Rs 602.7 crore, year-on-year, (YoY) basis.

  • Ipca Laboratories expects to clock 18-20% growth in FY12 May 25, 2011 01:26 PM IST

    Ipca Laboratories expects to clock 18-20% growth in FY12

    AK Jain, ED, Ipca Laboratories in an interview with CNBC-TV18 said that the company has projected normal growth of around 18-20% for the whole year. But if it receives the much awaited USFDA approval then it can register much higher growth ahead.

  • Ipca Lab Dec qtr PAT seen up 8.8% at Rs 63.4cr: Angel Jan 15, 2011 10:20 AM IST

    Ipca Lab Dec qtr PAT seen up 8.8% at Rs 63.4cr: Angel

    Angel Broking has come out with its earning estimates on the pharmaceutical sector for the quarter ended December 2010. According to the research firm, Ipca Laboratories December quarter net sales are expected to go up by 20.6% to Rs 475 crore, Year-on-Year, (Y-o-Y) basis.

  • Ipca Labs Dec qtr PAT seen up 28.6% at Rs 74.9cr: Karvy Jan 12, 2011 03:55 PM IST

    Ipca Labs Dec qtr PAT seen up 28.6% at Rs 74.9cr: Karvy

    Karvy Stock Broking has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Ipca Laboratories December quarter sales are expected to go up by 18% at Rs 467 crore, Year-on-Year, (YoY) basis.

Sections